Premaitha Health PLC Notice of AGM (3973L)
September 30 2016 - 9:38AM
UK Regulatory
TIDMNIPT
RNS Number : 3973L
Premaitha Health PLC
30 September 2016
Premaitha Health plc
("Premaitha" or the "Company")
Annual Report and Accounts and Notice of AGM
Manchester, UK - 30 September 2016 - Premaitha Health plc (AIM:
NIPT), developer of the leading CE-marked complete non-invasive
prenatal screening system, announces that its Annual Report and
Accounts for the year ended 31 March 2016 and Notice of Annual
General Meeting ("AGM") have today been posted to shareholders and
are available on the Company's website:
http://www.premaitha.com/.
Premaitha's AGM will be held at 2.00 p.m. on Thursday, 27
October 2016 at Greenheys Building, 61 Pencroft Way, Manchester M15
6JJ.
For more information, please contact:
Premaitha Health plc Tel: +44 (0)161
667 6865
Dr Stephen Little, Chief Executive investors@premaitha.com
Office
Barry Hextall, Chief Financial
Officer
Joanne Cross, Head of Marketing
Cairn Financial Advisers LLP (Nomad) Tel: +44 (0)20
7148 7900
Liam Murray
finnCap (Broker) Tel: +44 (0)20
7220 0500
Adrian Hargrave / Scott Mathieson
(Corporate Finance)
Tony Quirke (Corporate Broking)
Vigo Communications Tel: +44 (0)20
7830 9700
Ben Simons / Fiona Henson / Antonia
Pollock
premaitha@vigocomms.com
About Premaitha
Premaitha is a molecular diagnostics company which uses the
latest advances in DNA analysis technology to develop safer, faster
and regulatory approved non-invasive screening tests for pregnant
women.
Premaitha's lead test - the IONA(R) test - was launched in
February 2015 and is the leading CE marked complete system which
estimates the risk of a fetus being affected with Down's syndrome
or other genetic conditions. The IONA(R) test is performed on the
mother's blood sample - which contains traces of fetal DNA - and
then analysed using next generation DNA sequencing technology from
ThermoFisher Scientific.
Unlike existing prenatal screening methods, due to its high
level of accuracy, the IONA(R) test can significantly reduce the
number of women subjected to unnecessary stressful and invasive
follow-up diagnostic procedures which are costly, resource
intensive and carry a risk of miscarriage.
Non-invasive prenatal screening is an emerging, multi-billion
dollar global market and Premaitha's complete CE marked system
enables laboratories and health care practitioners to offer an
approved, non-invasive prenatal screening system in-house.
Premaitha is based in Manchester Science Park, United Kingdom
and its shares trade on the AIM market of the London Stock Exchange
(AIM: NIPT). For further information please visit
www.premaitha.com. Follow us on twitter @PremaithaHealth.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NOASDMFLSFMSEDU
(END) Dow Jones Newswires
September 30, 2016 10:38 ET (14:38 GMT)
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From Apr 2024 to May 2024
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From May 2023 to May 2024